References
1. Ferlay J, Parkin, DM, Steliarova-Foucher E. 2010. Estimates of cancer incidence and mortality in Europe in 2008. J. Cancer. Mar;46(4):765–781.
2. Siegel R, Naishadham D, Jemal A. 2012. Cancer statistics, 2012. CA Cancer. J Clin. Jan-Feb;62(1):10–29.
3. S. Cancer Statistics Working Group. 2013. United States Cancer Statistics: 1999–2010 Incidence and Mortality Web-based Report. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute.
4. Gilgunn S, Conroy PJ, Saldova R, Rudd PM, O'Kennedy RJ. 2013. Aberrant PSA glycosylation: a sweet predictor of prostate cancer. Nat Rev Urol. Feb;10(2):99-107.
5. Schmid M, Trinh QD, Graefen M, Fisch M, Chun FK, Hansen J. 2014. The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: Which markers matter and how should they be used? World J Urol. Aug:32(4):871-880.
6. Chevli KK, Duff M, Walter P, Yu C, Capuder B, Elshafei A, Malczewski S, Kattan MW, Jones JS. 2014. Urinary PCA3 as a Predictor of Prostate Cancer in a Cohort of 3,073 Men Undergoing Initial Prostate Biopsy. J Urol. Jun;191(6): 1743.
7. Goode RR, Marshall SJ, Duff M, Chevli E, Chevli 2013. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients. Prostate. Jan;73(1):48-53.
8. Stephan C, Ralla B, Jung 2014. Prostate-specific antigen and other serum and urine markers in prostate cancer. Biochim Biophys Acta. Aug;1846(1):99-112.
9. Taverna G, Tidu L, Grizzi F, Giusti G, Seveso M, Benetti A, Hurle R, Zandegiacomo S, Pasini L, Mandressi A, Graziotti P. 2014. Prostate cancer urine detection through highly-trained dogs' olfactory system: a real clinical opportunity. J Urol. Apr;191(4):1382-1387.